Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease

Journal of Pharmacology and Experimental Therapeutics

Volumn 330, Issue 3, 2009, Pages 964-970

  Willette, Robert N ^a   Eybye, Marianne E ^a   Olzinski, Alan R ^a   Behm, David J ^a   Aiyar, Nambi ^a   Maniscalco, Kristeen ^a   Bentley, Ross G ^a   Coatney, Robert W ^a   Zhao, Shufang ^a   Westfall, Timothy D ^a   Doe, Chris P ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [5 [5 (CYCLOPROPYLAMINO)CARBONYL] 3 FLUORO 2 METHYLPHENYL] N (2,2 DIMETHYLPROPYL) 3 PYRIDINE CARBOXAMIDE; ALDOSTERONE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; ROFECOXIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR DISEASE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DYSLIPIDEMIA; HEART LEFT VENTRICLE MASS; HEART OUTPUT; HEART STROKE VOLUME; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; SURVIVAL; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM; VASODILATATION;

ALDOSTERONE; ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOPROPANES; CYTOKINES; ELECTROCARDIOGRAPHY; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; INTERLEUKIN-1BETA; KIDNEY FUNCTION TESTS; LACTONES; LIPID METABOLISM; MALE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; RATS; RATS, INBRED SHR; RENIN; SULFONES; VASODILATION; VENTRICULAR REMODELING;

EID: 70349160825     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.154443     Document Type: Article

References (29)

1. Aw TJ, Haas SJ, Liew D, and Krum H (2005) Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 165:490-496. (Pubitemid 40344379)
2. Bao W, Behm DJ, Nerurkar SS, Ao Z, Bentley R, Mirabile RC, Johns DG, Woods TN, Doe CP, Coatney RW, et al. (2007) Effects of p38 MAPK inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production. J Cardiovasc Pharmacol 49:362-368. (Pubitemid 47000310)
3. Behm DJ, Herold CL, Ohlstein EH, Knight SD, Dhanak D, and Douglas SA (2002) Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys- Val- Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist. Br J Pharmacol 137:449-458. (Pubitemid 35221898)
4. Behr TM, Berova M, Doe CP, Ju H, Angermann CE, Boehm J, and Willette RN (2003) p38 mitogen-activated protein kinase inhibitors for the treatment of chronic cardiovascular disease. Curr Opin Investig Drugs 4:1059-1064. (Pubitemid 37321399)
5. Behr TM, Nerurkar SS, Nelson AH, Coatney RW, Woods TN, Sulpizio A, Chandra S, Brooks DP, Kumar S, Lee JC, et al. (2001) Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation 104:1292-1298. (Pubitemid 32848120)
6. Berg AH and Scherer PE (2005) Adipose tissue, inflammation, and cardiovascular disease [Review]. Circ Res 96:939-949. (Pubitemid 40712793)
7. Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier, et al. (1999) Rofecoxib [vioxx, MK- 0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5H)- furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 290:551-560. (Pubitemid 29344546)
8. Chenevard R, Hü rlimann D, Béchir M, Enseleit F, Spieker L, Hermann M, Riesen W, Gay S, Gay RE, Neidhart M, et al. (2003) Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 107:405-409.
9. De Tena JG, Kriszbacher I, Koppán M, Bódis J, and Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease [5] (multiple letters). N Engl J Med 353:429-430. (Pubitemid 41132355)
10. Forrester JS and Libby P (2007) The inflammation hypothesis and its potential relevance to statin therapy. Am J Cardiol 99:732-738.
11. Grundy SM (2003) Inflammation hypertension, and the metabolic syndrome. JAMA 290:3000-3002.
12. Ju H, Behm DJ, Nerurkar S, Eybye ME, Haimbach RE, Olzinski AR, Douglas SA, and Willette RN (2003) p38 MAPK inhibitors ameliorate target organ damage in hypertension. Part 1. p38 MAPK-dependent endothelial dysfunction and hypertension. J Pharmacol Exp Ther 307:932-938. (Pubitemid 37494209)
13. Ju H, Nerurkar S, Sauermelch CF, Olzinski AR, Mirabile R, Zimmerman D, Lee JC, Adams J, Sisko J, Berova M, et al. (2002) Sustained activation of p38 mitogenactivated protein kinase contributes to the vascular response to injury. J Pharmacol Exp Ther 301:15-20. (Pubitemid 34250274)
14. Li H, Hortmann M, Daiber A, Oelze M, Ostad MA, Schwarz PM, Xu H, Xia N, Kleschyov AL, Mang C, et al. (2008) Cyclooxygenase 2-selective and nonselective nonsteroidal anti-inflammatory drugs induce oxidative stress by up-regulating vascular NADPH oxidases. J Pharmacol Exp Ther 326:745-753.
15. Li Z, Tran TT, Ma JY, O'Young G, Kapoun AM, Chakravarty S, Dugar S, Schreiner G, and Protter AA (2004) p38 alpha mitogen-activated protein kinase inhibition improves cardiac function and reduces myocardial damage in isoproterenol-induced acute myocardial injury in rats. J Cardiovasc Pharmacol 44:486-492. (Pubitemid 39305091)
16. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, et al. (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation 109:1594-1602. (Pubitemid 38451714)
17. Morris JB, Olzinski AR, Bernard RE, Aravindhan K, Mirabile RC, Boyce R, Willette RN, and Jucker BM (2008) p38 MAPK inhibition reduces aortic ultrasmall superparamagnetic iron oxide uptake in a mouse model of atherosclerosis: MRI assessment. Arterioscler Thromb Vasc Biol 28:265-271. (Pubitemid 351161198)
18. Olzinski AR, McCafferty TA, Zhao SQ, Behm DJ, Eybye ME, Maniscalco K, Bentley R, Frazier KS, Milliner CM, Mirabile RC, et al. (2005) Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: Role of systemic blood pressure and endothelial protection. Cardiovasc Res 66:170-178. (Pubitemid 40357880)
19. Park JK, Fischer R, Dechend R, Shagdarsuren E, Gapeljuk A, Wellner M, Meiners S, Gratze P, Al-Saadi N, Feldt S, et al. (2007) p38 mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage. Hypertension 49:481-489. (Pubitemid 46263231)
20. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, Cipollone F, Ganci A, Créminon C, and Maclouf J (1994) Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 271:1705-1712. (Pubitemid 24382690)
21. Savoia C and Schiffrin EL (2007) Vascular inflammation in hypertension and diabetes: Molecular mechanisms and therapeutic interventions. Clin Sci 112:375-384. (Pubitemid 46587452)
22. Schieffer B, Bü nte C, Witte J, Hoeper K, Böger RH, Schwedhelm E, and Drexler H (2004) Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 44:362-368.
23. Schieven GL (2005) The biology of p38 kinase: a central role in inflammation. Curr Top Med Chemistry 5:921-928.
24. Touyz RM (2003) Recent advances in intracellular signalling in hypertension. Curr Opin Nephrol Hypertens 12:165-174. (Pubitemid 36288317)
25. Widder J, Behr T, Fraccarollo D, Hu K, Galuppo P, Tas P, Angermann CE, Ertl G, and Bauersachs J (2004) Vascular endothelial dysfunction and superoxide anion production in heart failure are p38 MAP kinase-dependent. Cardiovasc Res 63: 161-167. (Pubitemid 38759821)
26. Widlansky ME, Price DT, Gokce N, Eberhardt RT, Duffy SJ, Holbrook M, Maxwell C, Palmisano J, Keaney JF Jr, Morrow JD, et al. (2003) Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 42:310-315. (Pubitemid 37093478)
27. Willerson JT and Ridker PM (2004) Inflammation as a cardiovascular risk factor. Circulation 109:II-2-II-10.
28. Wong M, Jiang BY, McNeill K, Farish S, Kirkham B, and Chowienczyk P (2007) Effects of selective and non-selective cyclo-oxygenase inhibition on endothelial function in patients with rheumatoid arthritis. Scand J Rheumatol 36:265-269. (Pubitemid 47346916)
29. Zarraga IG and Schwarz ER (2007) Coxibs and heart disease. what we have learned and what else we need to know. J Am Coll Cardiol 49:1-14 (Pubitemid 46026890)